Sunshine Biopharma Announces that Essential 9TM is Now Available in the United States on Amazon.com


Sunshine Biopharma Inc.

Companies Mentioned:

Primary Exchange: OTC PINK
Under the Symbol: SBFM

($0.0005)

-7.0423


Thursday, May 16, 2019 10:35 AM

MONTREAL, QC / ACCESSWIRE / May 16, 2019 / Sunshine Biopharma, Inc. (OTC PINK: SBFM) today announced that its recently launched micronutrients supplement, Essential 9TM, is now available in the United States on www.Amazon.com. On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma to manufacture and sell the Essential 9TM product. Essential 9TM is a dietary supplement tablet that contains a balanced formula of the 9 essential amino acids that the human body cannot make. In addition to Amazon.com, Essential 9 is currently available on Amazon.ca. Sunshine Biopharma anticipates that Essential 9TM will soon be available on other Amazon websites.

About Essential 9TM

Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – from the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Sunshine Biopharma’s Essential 9TM provides all 9 essential amino acids in freeform and in the proportions recommended by Health Canada. Essential 9TM is suitable for everyone: vegans, athletes, seniors, dieters.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:

Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

SOURCE: Sunshine Biopharma, Inc.


SHARE ARTICLE

www.accesswire.com/viewarticle.aspx?id=545637

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these <abbr title="HyperText Markup Language">HTML</abbr> tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>




Done Reading? You might also find these links useful:
Stock Market News | Stocks Catalyst Calendar | Social Activity Stream | Stock Forums | Stocks Chat Rooms